PCD logo

Mapping the Overlap of Poverty Level and Prevalence of Diagnosed Chronic Kidney Disease Among Medicare Beneficiaries in the United States

Yun Han, PhD1; Fang Xu, PhD2; Hal Morgenstern, PhD3,4; Jennifer Bragg-Gresham, PhD1; Brenda W. Gillespie, PhD5; Diane Steffick, PhD1; William H. Herman, MD, MPH3,6; Meda E. Pavkov, MD, PhD2; Tiffany Veinot, PhD7; Rajiv Saran, MD1,3 (View author affiliations)

Suggested citation for this article: Han Y, Xu F, Morgenstern H, Bragg-Gresham J, Gillespie BW, Steffick D, et al. Mapping the Overlap of Poverty Level and Prevalence of Diagnosed Chronic Kidney Disease Among Medicare Beneficiaries in the United States. Prev Chronic Dis 2024;21:230286. DOI: http://dx.doi.org/10.5888/pcd21.230286.

PEER REVIEWED

High-resolution JPG for printimage iconimage iconimage icon

Geographic differences by county in CKD prevalence among US Medicare beneficiaries aged ≥65 years and in poverty levels, with higher rates of CKD in Florida and Appalachia (Panel A) and higher poverty levels in the Southeast (Panel B). Many counties in the South have both high poverty levels and a high prevalence of CKD, while many counties in the Northeast and Midwest have lower poverty levels but a high prevalence of CKD (Panel C). Abbreviation: CKD, chronic kidney disease. Data sources: Centers for Disease Control and Prevention (9); US Census Bureau (11). [A text version of this figure is available.]

Top

Background

Living in high-poverty neighborhoods has been identified as a contributing factor to the development and progression of chronic kidney disease (CKD) (1,2). High-poverty neighborhoods often face inequities related to social determinants of health, such as lower incomes; gaps in educational achievement; inadequate access to healthy food, health care, green space, and high-quality recreational facilities; and greater exposure to air and water pollution (3–8). A limited ability to purchase healthy food and access recreational facilities and preventive health care can delay diagnosis and timely management of CKD. Understanding the distribution of CKD at the county level in relation to poverty level is important: this knowledge can guide population-level interventions for CKD prevention and management. The objectives of this study were to examine the county-level association between poverty level and diagnosed CKD and to illustrate county-level bivariate distribution of poverty and CKD among Medicare fee-for-service beneficiaries aged 65 years or older in the US.

Top

Methods

We calculated the county-level prevalence of diagnosed CKD in each US county among Medicare fee-for-service beneficiaries aged 65 years or older based on 5% claims data for 2019. The study population included beneficiaries who had full-year Parts A and B enrollment and at least 1 inpatient or outpatient visit in 2019. The numerator of CKD prevalence included eligible beneficiaries with at least 1 claim in 2019 containing an ICD-10-CM (International Classification of Diseases, Tenth Revision, Clinical Modification) diagnosis code for CKD (9,10). We excluded beneficiaries with end-stage kidney disease because they are not at risk for CKD. We also excluded Medicare beneficiaries covered by Part C (managed care/Medicare Advantage plans) because of limited availability of data. The total study population consisted of 1,234,056 beneficiaries in 3,097 counties (98.5% of all 3,143 US counties).

Poverty level was measured as the percentage of the total county population below the poverty threshold extracted from the American Community Survey 5-year data (2015–2019) (11).

We linked measurements of CKD and poverty by using county Federal Information Processing Standards (FIPS) codes. We standardized county-level prevalence of CKD based on strata of demographic characteristics. The 5% sample of the 2019 Medicare population aged 65 years or older (ie, the study population) served as the standard population. We performed 3 analyses: 1) a crude (unstandardized) analysis; 2) standardization on age alone (age categories 65–69, 70–79, 80–89, ≥90 y); and 3) standardization on age, sex (male, female), and race and ethnicity (White, Black, Hispanic, Asian, other [American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, other], unknown).

We then generated 2 univariate choropleth (color-coded or shaded) maps to separately depict crude county-level distributions of CKD prevalence and poverty levels across the US. In addition, we created a bivariate map (in R version 4.3.1 [R Foundation for Statistical Computing]) that combines the distributions of both variables in each county by using a 2-dimensional (3 × 3) key to show the tertile (high, medium, low) of CKD prevalence and poverty level. Thus, the color of each county represents the association between county poverty level and CKD prevalence, and the bivariate map shows the pattern of those associations across the US, emphasizing the clustering and geographic patterns of counties. Data were suppressed for counties with 10 or fewer beneficiaries (n = 108, 3.4% of all counties) according to the Centers for Medicare & Medicaid Services small-cell suppression rule to protect privacy (12). This suppression had only a minor effect on the map’s appearance, but it may have led to underrepresentation of counties with smaller populations of older adults.

Top

Highlights

The mean (SD) county-level crude prevalence of CKD in the study population was 22.1% (6.5%). The mean (SD) prevalence of poverty was 15.4% (6.9%). As the poverty level increased, the crude prevalence of CKD also rose, from 20.9% to 23.4% (Table). This pattern was nearly the same when standardized measures were used (Table), suggesting that age, sex, and race and ethnicity did not confound the association between poverty-level tertile and CKD prevalence.

We observed considerable geographic variations in crude CKD prevalence (Figure A) and poverty level (Figure B). CKD prevalence was higher in Florida and the Appalachian region, which encompasses parts of Ohio, Pennsylvania, West Virginia, Kentucky, Tennessee, and Alabama (Figure A). Poverty levels were clustered, with a high concentration of counties east of the Mississippi River having higher poverty levels (Figure B).

The bivariate map (Figure C) shows the underlying joint distribution of county-level poverty and CKD prevalence. Many counties in the Southeast show high levels of both poverty and CKD, and many counties in New England show low levels of both poverty and CKD. Both patterns indicate a positive association between the 2 measures (high–high or low–low). In contrast, several counties in the mid-Atlantic coast and the upper Midwest show high CKD prevalence and low poverty level, and many counties in the West show high levels of poverty level and low CKD prevalence, indicating an inverse association between the 2 measures (high–low or low–high).

Top

Action

The observed spatial disparities in CKD and poverty suggest that a one-size-fits-all intervention may not be effective in decreasing the prevalence of CKD. Tailored interventions for older adults are necessary. In high-prevalence/high-poverty counties, interventions could focus on local challenges among older adults by improving health care access, addressing socioeconomic barriers to health, and implementing strategies such as subsidized healthy food programs and enhanced health care services. Conversely, in high-prevalence/low-poverty counties, strategies could encompass health education and disease management programs, with a focus on public awareness campaigns about CKD risk factors and promotion of regular health screenings. In these counties, factors other than economic status, including prevalence of comorbidities, health care access, environmental conditions, and lifestyle choices, may influence the prevalence of CKD.

Although our study sheds light on the correlation between county-level poverty and the prevalence of CKD, it has limitations in addressing the multifaceted nature of poverty. First, individual-level poverty, which encompasses personal financial constraints and limited access to health care, also plays a crucial role in CKD risk. Our focus on county-level data may not fully capture individual poverty experiences and their direct effect on CKD. Studies incorporating individual-level socioeconomic data could enhance the understanding of the complex interplay between poverty and CKD prevalence. Second, we identified CKD based on ICD-10-CM diagnosis codes because we lacked laboratory data (eg, estimated glomerular filtration rate). This reliance on diagnosis codes may have resulted in an underestimation of actual CKD prevalence and possible distortions in observed geographic patterns. A third limitation is the choice of geographic unit; using county-level data may mask finer-scale variations and socioeconomic disparities, particularly in urban areas. Fourth, our cross-sectional study examined the relationship between county-level poverty and CKD prevalence at a single time point. As highlighted by Lapedis et al (13), a cross-sectional approach may not fully encapsulate the complex and evolving relationship between neighborhood characteristics and the various stages of CKD, particularly the early stages. The reliance on a single time-point analysis limits our ability to understand these dynamics over the life course. Overall, further research, accounting for confounders and mediators, may be essential to delve into the underlying causes of the observed spatial disparities in CKD and poverty. This research includes identifying factors contributing to high CKD prevalence in low-poverty counties in the Northeast and Midwest. These findings may guide clinical practice and health policy aimed at mitigating CKD disparities across the US.

Top

Acknowledgments

The publication acknowledges the contribution of resources and facilities provided by the University of Michigan, Ann Arbor, Michigan. This work was supported by the Supporting, Maintaining and Improving the Surveillance System for Kidney Disease in the US (NU58DP006956), funded by the Centers for Disease Control and Prevention. The CKD Surveillance Team at CDC comprises a dedicated group of individuals, including Michael Heung, MD; Zubin Modi, MD; Vahakn Shahinian, MD; Yam Hoon Lim, MEd; Miao Yu, MS; Ana Licon, MS; Jenna Kiryakos, MPH; Austin Stack, MD; and Joe Vassalotti, MD. Rajiv Saran, MD, is principal investigator. The authors have no conflicts of interest to disclose. No copyrighted material, surveys, instruments, or tools were used in this research. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of CDC.

Top

Author Information

Corresponding Author: Rajiv Saran, MD, Department of Internal Medicine, Division of Nephrology, University of Michigan, 1500 E Medical Center Dr, Ann Arbor, MI 48105 (rsaran@med.umich.edu).

Author Affiliations: 1Department of Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor. 2Division of Diabetes Translation, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia. 3Department of Epidemiology, University of Michigan, Ann Arbor. 4Departments of Environmental Health Sciences and Urology, University of Michigan, Ann Arbor. 5Department of Biostatistics, University of Michigan, Ann Arbor. 6Department of Internal Medicine, Division of Metabolism, Endocrinology, and Diabetes, University of Michigan, Ann Arbor. 7School of Information, University of Michigan, Ann Arbor.

Top

References

  1. Patzer RE, McClellan WM. Influence of race, ethnicity and socioeconomic status on kidney disease. Nat Rev Nephrol. 2012;8(9):533–541. PubMed doi:10.1038/nrneph.2012.117
  2. Hossain MP, Goyder EC, Rigby JE, El Nahas M. CKD and poverty: a growing global challenge. Am J Kidney Dis. 2009;53(1):166–174. PubMed doi:10.1053/j.ajkd.2007.10.047
  3. Houlihan J, Leffler S. Assessing and addressing social determinants of health: a key competency for succeeding in value-based care. Prim Care. 2019;46(4):561–574. PubMed doi:10.1016/j.pop.2019.07.013
  4. Schroeder SA. Shattuck Lecture. We can do better — improving the health of the American people. N Engl J Med. 2007;357(12):1221–1228. PubMed doi:10.1056/NEJMsa073350
  5. Bibbins-Domingo K. Integrating social care into the delivery of health care. JAMA. 2019;322(18):1763–1764. PubMed doi:10.1001/jama.2019.15603
  6. Soderland P, Lovekar S, Weiner DE, Brooks DR, Kaufman JS. Chronic kidney disease associated with environmental toxins and exposures. Adv Chronic Kidney Dis. 2010;17(3):254–264. PubMed doi:10.1053/j.ackd.2010.03.011
  7. Wen M, Zhang X, Harris CD, Holt JB, Croft JB. Spatial disparities in the distribution of parks and green spaces in the USA. Ann Behav Med. 2013;45(Suppl 1):S18–S27. PubMed doi:10.1007/s12160-012-9426-x
  8. McKenzie TL, Moody JS, Carlson JA, Lopez NV, Elder JP. Neighborhood income matters: disparities in community recreation facilities, amenities, and programs. J Park Recreat Admi. 2013;31(4):12–22. PubMed
  9. Centers for Disease Control and Prevention. Kidney Disease Surveillance System. Prevalence of diagnosed CKD among Medicare beneficiaries aged ≥65 years, by U.S. state and county. Accessed August 10, 2023. https://nccd.cdc.gov/CKD/detail.aspx?Qnum=Q705
  10. Centers for Disease Control and Prevention. International Classification of Diseases, Tenth Revision, Clinical Modification. Last reviewed June 29, 2023. Accessed February 21, 2024. https://www.cdc.gov/nchs/icd/icd-10-cm.htm
  11. US Census Bureau. 2015–2019 ACS 5-year estimates. Page last revised December 8, 2021. Accessed February 21, 2024. https://www.census.gov/programs-surveys/acs/technical-documentation/table-and-geography-changes/2019/5-year.html
  12. Centers for Medicare & Medicaid Services. CMS cell suppression policy. January 1, 2020. Accessed August 10, 2023. https://www.hhs.gov/guidance/document/cms-cell-suppression-policy
  13. Lapedis CJ, Mariani LH, Jang BJ, Hodgin J, Hicken MT. Understanding the link between neighborhoods and kidney disease. Kidney360. 2020;1(8):845–854. PubMed doi:10.34067/KID.0001202019

Top

Table

Return to your place in the text

Table. Crude and Standardized Prevalence of Diagnosed Chronic Kidney Disease Among Medicare Beneficiaries Aged ≥65 Years, by Tertile of County Poverty Level (N = 3,097), United States, 2019a
Prevalence All Tertile of county poverty levelb
Low Medium High
Crude 22.1 (6.5) 20.9 (6.0) 22.1 (6.2) 23.4 (7.0)
Standardized for agec 22.2 (6.6) 21.0 (6.2) 22.2 (6.3) 23.5 (7.1)
Standardized for age, sex, and race and ethnicityc 22.0 (6.9) 20.8 (6.4) 22.0 (6.4) 23.0 (7.6)

Abbreviation: CKD, chronic kidney disease.
a Data source: 2019 Medicare 5% Sample Data and American Community Survey data (2015−2019) (11). All values are mean (SD).
b Tertile breaks were used to create the categories for all data from the study population for poverty level (expressed as percentage of the population below the federal poverty threshold): low, < 12%; medium, 12%–17%; high, > 17%).
c Standardization was based on strata for age (65−70, 70−80, 80−90, >90 y), sex, and race and ethnicity (White, Black, Hispanic, Asian, other [American Indian/Alaska Native, Native Hawaiian/Other Pacific Islander, other], unknown). The standard population was Medicare fee-for-service beneficiaries aged ≥65 years in 2019.

Top


The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions.